Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Oncorena in connection with share issue
Mandate

Vinge advises Oncorena in connection with share issue

July 30, 2025 Capital Markets and Public M&A Life Sciences & Health

Vinge advises Oncorena Holding AB in connection with a share issue of approximately SEK 133 million.

The issue proceeds will be used to complete the second part of the clinical study Oncorella-1, which is a phase 1/2 study of safety, tolerability, and anti-tumor efficacy of treatment with ONC175 (Oncorena’s investigational drug product under development) for patients with metastatic clear cell, or papillary renal cell carcinoma, mRCC.

The Vinge team includes Christian Lindhé, Martin Madsen Svanberg and Nathalie Wikman.

Related

Vinge advises Karl Hedin and minority owners on the sale of AB Karl Hedin Sågverk to Vida

 Vinge has advised Karl Hedin and minority shareholders in connection with the sale of AB Karl Hedin Sågverk to Vida Aktiebolag (“Vida”).
July 24, 2025

Vinge advises OsteoCentric on the public offer for Integrum

 OsteoCentric Oncology and Bone Anchored Prostheses, LLC, a subsidiary of OsteoCentric Technologies, Inc., has made a public offer for all shares in Integrum AB (publ). The offer values all shares in Integrum at approximately SEK 939 million.
July 23, 2025

Vinge advises Investor on its co-investment in the SEK 55 billion public offer for Fortnox led by EQT X

 Vinge advises Investor AB (publ) (“Investor”) on its co-investment in the public offer for Fortnox AB (publ) (“Fortnox”) led by EQT X together with First Kraft AB (owned by Olof Hallrup), acting through Omega II AB (“Omega II”). Fortnox offers vital software infrastructure to small and medium-sized companies in Sweden with a track record of profitable growth.
July 22, 2025